Neurology Medical News about Glypican 5;interferon-beta response gene

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Glypican 5 is an interferon-beta response gene: A replication study
Multiple Sclerosis, 06/30/09

Cenit MDC et al. – Results confirm an association of polymorphisms within GPC5 with response to interferon-beta therapy in pts with multiple sclerosis (MS).

Methods

Study to replicate results from 2 loci most strongly implicated in response to interferon-beta treatment, HAPLN1 and GPC5
Case–control study, analyzing 199 MS pts treated with interferon-beta for ≥2 yrs and ≥2 documented relapses over 2 yrs, previous to treatment onset
Assessment of 3 single-nucleotide polymorphisms (SNPs) in GPC5 locus and 3 SNPs in HAPLN1 locus by TaqMan technology
Comparison of allelic frequencies between responders and nonresponders by chi-square test

Results

Responders had neither relapses nor increase in expanded disability status scale (EDSS) over 2-yr follow-up period
Nonresponders had ≥2 relapses or an increase in EDSS of ≥1 point
Association between GPC5 polymorphisms and response to interferon-beta therapy in MS pts, in agreement with earlier data
The other locus studied (HAPLN1) did not show association with treatment response to interferon-beta